We Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Soon [Yahoo! Finance]
Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ:AMEX Investor Relations:
ir.citiuspharma.com
Company Research
Source: Yahoo! Finance
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. The US$19m market-cap company posted a loss in its most recent financial year of US$37m and a latest trailing-twelve-month loss of US$36m shrinking the gap between loss and breakeven. As path to profitability is the topic on Citius Pharmaceuticals' investors mind, we've decided to gauge market sentiment. Below we will provide a high-level summary of the industry analysts' expectations for the company. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. Expectations from some of the American Pharmaceuticals analysts is that Citius Pharmaceuticals is on the verge of breakeven. They anticipate the company to incur a final loss in 2025, before generating positive profits of US$36m in 2026. The company is therefore projected to breakeven around 12 months from now or less. How fast will the
Show less
Read more
Impact Snapshot
Event Time:
CTXR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTXR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTXR alerts
High impacting Citius Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CTXR
News
- Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq RulesPR Newswire
- Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules [TheStreet.com]TheStreet.com
- Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq RulesPR Newswire
- Citius Pharmaceuticals (CTXR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $6.00 price target on the stock.MarketBeat
- Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR [Yahoo! Finance]Yahoo! Finance
CTXR
Earnings
- 5/14/25 - Beat
CTXR
Sec Filings
- 4/29/26 - Form 8-K
- 4/24/26 - Form 8-K
- 4/24/26 - Form 424B5
- CTXR's page on the SEC website